Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 4:59 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 3,875 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: fast Clear all

Conditions: Healthy Volunteers
Interventions: Questionnaire, Stool sample, Skin swab, Oral rinse; Other
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2030
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Solid Tumors, Lymphoma
Interventions: PU-H71; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Gestational Diabetes Mellitus as Antepartum Condition
Interventions: myo-inositol, Continuous glucose monitoring surveillance, Glucose monitoring; Dietary Supplement · Device
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 13 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Retinal Diseases, Optic Nerve Diseases
Interventions: Duke Biomedical Engineering's Long-working distance OCT; Device
Lead sponsor: Duke University; Other
Eligibility: 6 Months and older
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Healthy
Interventions: Gabapentin 800 mg tablets, single dose (1 tablet), NEURONTIN® 400 mg capsules, single dose (2 capsules); Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Ebola Virus Disease, Marburg Virus Disease
Interventions: cAd3-Marburg, cAd3-EBO-S; Biological
Lead sponsor: Albert B. Sabin Vaccine Institute; Other
Eligibility: 18 Years to 50 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Type 1 Diabetes Mellitus
Interventions: Ultra-Rapid Lispro, Insulin Lispro; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 471 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 32
States / cities: Concord, California • Fresno, California • Greenbrae, California + 28 more

Conditions: Colonic Neoplasms
Interventions: Normal (0.9%) saline, HalfLytely; Drug
Lead sponsor: Arya, Vijaypal, M.D., P.C.; Individual
Eligibility: 21 Years to 70 Years
Enrollment: 133 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Middle Village, New York

Conditions: Symptomatic Neurogenic Orthostatic Hypotension
Interventions: Droxidopa; Drug
Lead sponsor: Chelsea Therapeutics; Industry
Eligibility: 65 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Preterm Infant
Interventions: Early/Slow, Early/Fast, Late/Slow, Late/Fast; Other
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Up to 32 Weeks
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Poor Glycemic Control
Interventions: Metformin, Glargine insulin, Glulisine; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Type 1 Diabetes, De Novo Lipogenesis
Interventions: Oral Glucose Tolerance Test; Diagnostic Test
Lead sponsor: Yale University; Other
Eligibility: 13 Years to 22 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Superior Vena Cava Syndrome
Interventions: Superior vena cava reconstruction; Procedure
Lead sponsor: Methodist Health System; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Adverse Reaction to Drug, Health Behavior, Medication Adherence, Physician-Patient Relations
Interventions: Personal Health Record (PHR); Behavioral
Lead sponsor: University of Iowa; Other
Eligibility: 65 Years to 95 Years
Enrollment: 1,163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Spinal Cord Injuries, Cardiovascular Diseases, Endothelial Dysfunction
Interventions: Brachial intra-arterial infusion of vasoactive and antioxidant drugs (acetylcholine, nitroprusside, ascorbic acid), venous occlusion plethysmography, Acetylcholine, Sodium Nitroprusside, Ascorbic acid, venous phlebotomy; Procedure · Drug
Lead sponsor: Craig Hospital; Other
Eligibility: 18 Years to 89 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Englewood, Colorado

Conditions: Obesity, Childhood
Interventions: protein-sparing modified fast diet; Other
Lead sponsor: Ihuoma Eneli; Other
Eligibility: 11 Years to 19 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Healthy
Interventions: Clarithromycin, Biaxin®; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002
U.S. locations: 2
States / cities: East Grand Forks, Minnesota • Fargo, North Dakota

Conditions: Food Choices
Interventions: Control (QR) Labels, Low Sustainability Labels, Unsustainable Labels, Environmental Harm Labels, High Environmental Harm Labels, High Environmental Cost Labels, Numeric Environmental Cost Labels; Behavioral
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 18 Years and older
Enrollment: 14,720 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: type1diabetes, Obesity
Interventions: Hyperinsulinemic-euglycemic clamp, High Fat Mixed Meal Tolerance Test; Biological · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 30 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy Volunteer
Interventions: GDC-0032 Phase III Tablet, GDC-0032 Tablet, GDC-0032 Capsule; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Infections, Bacterial
Interventions: GSK1322322 1000 mg containing radioactive 14C-GSK1322322, GSK1322322 1200 mg containing radioactive 14C-GSK1322322; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 30 Years to 55 Years · Male only
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Screening Breast MRI in Patients Who Are BRCA Mutation Carriers
Interventions: MRI, Optional Screening Questionnaire; Device · Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 30 Years and older · Female only
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Cataract
Interventions: Printed Instructions with Phone Reminders, Sharp Health Companion App (CareKit); Behavioral
Lead sponsor: Sharp HealthCare; Other
Eligibility: Not listed
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: San Diego, California

Conditions: Exposure, Environmental, Genetic Predisposition
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 100,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2035
U.S. locations: 1
States / cities: Rochester, Minnesota

Search by objective public record fields.

Human Skin and Gut Mycobiome and Bacteriome Comprehensive Registry

PU-H71 in Patients With Solid Tumors and Low-Grade Non-Hodgkin's Lymphoma That Have Not Responded to Standard Treatment

Glycemic Impact of Myo-inositol in Pregnancy

Long-Working Distance OCT for Children

A Limited Food Effect Study of Gabapentin 800 mg Tablets

Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults

A Study Comparing LY900014 to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes Using Insulin Pump Therapy

Yoga and Bolus Lukewarm Saline as Rapid Colonoscopy Preparation

Study of the Fed-Fast Pharmocokinetics and Bioequivalance of 300mg Capsules of Droxidopa

Testing Four Feeding Approaches to Oral Feeding in Preterm Infants

Efficacy and Safety of a Glargine-based Hospital Discharge Algorithm in Coronary Artery Bypass Graft (CABG) Patients

Pathogenesis of the Cardiometabolic Risk in Youth With Type 1 Diabetes

Superior Vena Cava Reconstruction in Patients on Hemodialysis

Personal Health Records and Elder Medication Use Quality

Role of Endothelial Function in SCI CVD Risk

A Protein-sparing Modified Fast for Children and Adolescents With Severe Obesity (PSMF)

Clarithromycin 500 mg Tablets Under Fasting Conditions

Perceptions of and Reactions to Sustainability Menu Label Designs

Physiologic Markers of Cardiometabolic Risk in People With Type 1 Diabetes

A Study to Evaluate the Effect of Particle Size, Formulation and Food on the Pharmacokinetics of GDC-0032 in Healthy Volunteers

A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C -GSK1322322 After an Intravenous and an Oral Dose

Rapid Pancreatic and Ovarian Screening MR Imaging With Motion Corrected T1, T2, and Advanced Diffusion Weighted Imaging for Patients With BRCA Mutation Who Undergo Screening Breast MRI

Sharp Health Companion App for Cataract Surgery Preparation and Recovery

Precure Targeted Accrual and Rapid Growth in Enrollment Trial Study